EMFLAZA is a Oral Suspension in the Human Prescription Drug category. It is labeled and distributed by Marathon Pharmaceuticals, Llc. The primary component is Deflazacort.
| Product ID | 42998-505_4e001bac-ce04-4262-96f4-8b23161f9e55 |
| NDC | 42998-505 |
| Product Type | Human Prescription Drug |
| Proprietary Name | EMFLAZA |
| Generic Name | Deflazacort |
| Dosage Form | Suspension |
| Route of Administration | ORAL |
| Marketing Start Date | 2017-02-09 |
| Marketing End Date | 2020-06-30 |
| Marketing Category | NDA / NDA |
| Application Number | NDA208685 |
| Labeler Name | Marathon Pharmaceuticals, LLC |
| Substance Name | DEFLAZACORT |
| Active Ingredient Strength | 23 mg/mL |
| Pharm Classes | Corticosteroid [EPC],Corticosteroid Hormone Receptor Agonists [MoA] |
| NDC Exclude Flag | N |
| Marketing Start Date | 2017-02-09 |
| NDC Exclude Flag | N |
| Sample Package? | N |
| Marketing Category | NDA |
| Application Number | NDA208685 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Billing Unit | ML |
| Marketing Start Date | 2017-02-09 |
| Marketing End Date | 2020-06-30 |
| Ingredient | Strength |
|---|---|
| DEFLAZACORT | 22.75 mg/mL |
| SPL SET ID: | c1d8a24e-96d4-4e3a-8f7e-b9c2dc060b1f |
| Manufacturer | |
| UNII | |
| RxNorm Concept Unique ID - RxCUI |
| NDC | Brand Name | Generic Name |
|---|---|---|
| 42998-501 | EMFLAZA | deflazacort |
| 42998-502 | EMFLAZA | deflazacort |
| 42998-503 | EMFLAZA | deflazacort |
| 42998-504 | EMFLAZA | deflazacort |
| 42998-505 | EMFLAZA | deflazacort |
| 52856-501 | EMFLAZA | deflazacort |
| 52856-502 | EMFLAZA | deflazacort |
| 52856-503 | EMFLAZA | deflazacort |
| 52856-504 | EMFLAZA | deflazacort |
| 52856-505 | EMFLAZA | deflazacort |
Mark Image Registration | Serial | Company Trademark Application Date |
|---|---|
![]() EMFLAZA 86639624 5261599 Live/Registered |
PTC THERAPEUTICS, INC. 2015-05-22 |